Related Experiment Video
Updated: Jun 12, 2026

BioMEMS: Forging New Collaborations Between Biologists and Engineers
Published on: November 1, 2007
The FDA and the new biology
Robert D Simari1, Horng Chen, John C Burnett
1Division of Cardiovascular Diseases, Heart and Lung Research Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. simari.robert@mayo.edu
Abstract:
The translation of basic science discoveries to clinical application is dependent on the demonstrated efficacy in humans of the technology but even as importantly on the therapeutic agent or device conforming to the standards of the US Food and Drug Administration (FDA) leading to approval. In this editorial, we propose that the FDA consider a modified process to support the more rapid development of novel agents while furthering the understanding of the risk and benefits of new therapeutics as they are utilized following approval.
Related Concept Videos
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Regulation
The Central Dogma
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
FDA Approved Drugs: Changes to Approved Drugs
Bioequivalence studies: Biowaivers

